Shanghai Anmai Biotechnology

Shanghai Anmai Biotechnology is a biopharmaceutical company specializing in the development of next-generation gene therapies using advanced Adeno-Associated Virus (AAV) vector technology. Founded in 2021 and headquartered in Shanghai, the company leverages its proprietary AAV-LP platform for capsid engineering to create vectors with improved tissue specificity, enhanced potency, and reduced immunogenicity. Anmai's pipeline targets a range of conditions with high unmet medical needs, including hemophilia B, wet age-related macular degeneration, and Fabry disease. The company integrates its research and development efforts with internal GMP-compliant manufacturing capabilities to accelerate the transition of its candidates from discovery to clinical trials. Supported by a consortium of leading venture capital firms, Anmai is positioned as an innovative player in the global gene therapy landscape.